Open an account

Tyra Biosciences

TYRA · NASDAQ

$20.47+$1.13 (+5.84%)TodayMarket closed ·
Prev close $19.34

About TYRA

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company is headquartered in Carlsbad, California and currently employs 87 full-time employees. The company went IPO on 2021-09-15. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. The company has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. The company is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.

Employees
87
Headquarters
Carlsbad, California
Listed
Sep 15, 2021
Sector
Health Care
Industry
Biotechnology
Website
tyra.bio

TYRA key statistics

Market cap
1.41B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
790.88K
Volume
606.71K
Open price
$19.42
High today
$20.58
Low today
$19.35
52 Week high
$40.65
52 Week low
$13.35

Tyra Biosciences (TYRA) at a glance

As of Oct 20, 2026, Tyra Biosciences (TYRA) shares are priced at $20.47, giving the company a market cap of 1.41B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $19.35 and $20.58. The current price is 5.8% above the day's low and 0.5% below its high.

Volume so far is 606.71K shares, below the average of 790.88K shares a day.

Over the past year Tyra Biosciences has ranged from $13.35 to $40.65, and now sits 26% of the way up that range.

Tyra Biosciences met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.69 per share against an estimate of -$0.6626.

The average analyst price target is $48.40, 136.5% above the current price, from 13 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

92%of 13 analyst ratings say Buy
  • Buy92.3%
  • Hold7.7%
  • Sell0.0%
Price target · 13 analystsAvg $48.40
Low
$29.29
Now
$20.47
High
$61.95

TYRA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 8.1% on average.

  1. Q3 FY24: reported -$0.41 per share against an estimate of -$0.4067
  2. Q4 FY24: reported -$0.43 per share against an estimate of -$0.4901
  3. Q1 FY25: reported -$0.47 per share against an estimate of -$0.4994
  4. Q2 FY25: reported -$0.47 per share against an estimate of -$0.5393
  5. Q3 FY25: reported -$0.50 per share against an estimate of -$0.5075
  6. Q4 FY25: reported -$0.57 per share against an estimate of -$0.5387
  7. Q1 FY26: reported -$0.64 per share against an estimate of -$0.6044
  8. Q2 FY26: reported -$0.69 per share against an estimate of -$0.6626

TYRA news

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

  • Rishabh Mishra

    Stock Market Today: S&P 500, Dow and Nasdaq Futures Fall as Brent Hovers Near $107 and FOMC Commences Two-Day Meeting— MSTR, CRWD, BMM in Focus (UPDATED)

  • Avi Kapoor

    Crude Oil Jumps 3%; Corning Shares Move Lower

  • Press releasePRNewswire

    Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Similar companies

Companies in the same industry as Tyra Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.